Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate
Author:
Addetia AminORCID, Crawford Katharine HDORCID, Dingens AdamORCID, Zhu Haiying, Roychoudhury Pavitra, Huang Meei-Li, Jerome Keith R., Bloom Jesse D.ORCID, Greninger Alexander L.ORCID
Abstract
AbstractThe development of vaccines against SARS-CoV-2 would be greatly facilitated by the identification of immunological correlates of protection in humans. However, to date, studies on protective immunity have only been performed in animal models and correlates of protection have not been established in humans. Here, we describe an outbreak of SARS-CoV-2 on a fishing vessel associated with a high attack rate. Predeparture serological and viral RT-PCR testing along with repeat testing after return to shore was available for 120 of the 122 persons on board over a median follow-up of 32.5 days (range 18.8 to 50.5 days). A total of 104 individuals had an RT-PCR positive viral test with Ct <35 or seroconverted during the follow-up period, yielding an attack rate on board of 85.2% (104/122 individuals). Metagenomic sequencing of 39 viral genomes suggested the outbreak originated largely from a single viral clade. Only three crewmembers tested seropositive prior to the boat’s departure in initial serological screening and also had neutralizing and spike-reactive antibodies in follow-up assays. None of these crewmembers with neutralizing antibody titers showed evidence of bona fide viral infection or experienced any symptoms during the viral outbreak. Therefore, the presence of neutralizing antibodies from prior infection was significantly associated with protection against re-infection (Fisher’s exact test, p=0.002).
Publisher
Cold Spring Harbor Laboratory
Reference50 articles.
1. Corbett KS , Flynn B , Foulds KE , Francica JR , Boyoglu-Barnum S , Werner AP , Flach B , O’Connell S , Bock KW , Minai M , Nagata BM , Andersen H , Martinez DR , Noe AT , Douek N , Donaldson MM , Nji NN , Alvarado GS , Edwards DK , Flebbe DR , Lamb E , Doria-Rose NA , Lin BC , Louder MK , O’Dell S , Schmidt SD , Phung E , Chang LA , Yap C , Todd J-PM , Pessaint L , Van Ry A , Browne S , Greenhouse J , Putman-Taylor T , Strasbaugh A , Campbell T-A , Cook A , Dodson A , Steingrebe K , Shi W , Zhang Y , Abiona OM , Wang L , Pegu A , Yang ES , Leung K , Zhou T , Teng I-T , Widge A , Gordon I , Novik L , Gillespie RA , Loomis RJ , Moliva JI , Stewart-Jones G , Himansu S , Kong W-P , Nason MC , Morabito KM , Ruckwardt TJ , Ledgerwood JE , Gaudinski MR , Kwong PD , Mascola JR , Carfi A , Lewis MG , Baric RS , McDermott A , Moore IN , Sullivan NJ , Roederer M , Seder RA , Graham BS . 2020. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine 0:null. 2. van Doremalen N , Lambe T , Spencer A , Belij-Rammerstorfer S , Purushotham JN , Port JR , Avanzato VA , Bushmaker T , Flaxman A , Ulaszewska M , Feldmann F , Allen ER , Sharpe H , Schulz J , Holbrook M , Okumura A , Meade-White K , Pérez-Pérez L , Edwards NJ , Wright D , Bissett C , Gilbride C , Williamson BN , Rosenke R , Long D , Ishwarbhai A , Kailath R , Rose L , Morris S , Powers C , Lovaglio J , Hanley PW , Scott D , Saturday G , de Wit E , Gilbert SC , Munster VJ . 2020. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 1-8. 3. Development of an inactivated vaccine candidate for SARS-CoV-2 4. A human monoclonal antibody blocking SARS-CoV-2 infection 5. Ju B , Zhang Q , Ge J , Wang R , Sun J , Ge X , Yu J , Shan S , Zhou B , Song S , Tang X , Yu J , Lan J , Yuan J , Wang H , Zhao J , Zhang S , Wang Y , Shi X , Liu L , Zhao J , Wang X , Zhang Z , Zhang L . 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature https://doi.org/10.1038/s41586-020-2380-z.
Cited by
119 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|